荟萃分析的白介素2受体拮抗剂治疗Steroid-Refractory急性移植物抗宿主病。

文章的细节

引用

复制到剪贴板

沈MZ,李JX张XH,徐LP王Y,刘肯塔基州,黄XJ,香港SD,莫XD

荟萃分析的白介素2受体拮抗剂治疗Steroid-Refractory急性移植物抗宿主病。

Immunol前面。2021年9月21日,12:749266。doi: 10.3389 / fimmu.2021.749266。eCollection 2021。

PubMed ID

34621279 (在PubMed

]

文摘

急性移植物抗宿主病(aGVHD)是一个主要的并发症后同种异体造血干细胞移植(HSCT)。皮质类固醇是aGVHD的一线治疗,但其反应率仅约50%。目前,没有统一接受治疗steroid-refractory aGVHD (SR-aGVHD)是可用的。阻断白介素2受体(IL-2Rs)使用制药拮抗剂减轻SR-aGVHD供者T细胞。这个荟萃分析旨在比较疗效和安全性四个商用IL-2R拮抗剂(IL-2RAs) SR-aGVHD治疗。共有31个研究遇到以下入选标准(1):病人的任何种族,任何性行为,和所有年龄(2);那些被诊断为SR-aGVHD HSCT后;和(3)使用IL-2RA-based疗法作为治疗SR-aGVHD。整体反应率(ORR)治疗后的任何时候basiliximab和daclizumab是0.81(95%可信区间(CI): 0.74 - -0.87)和0.71(95%置信区间:0.56—-0.82),分别是优于inolimomab 0.54(95%置信区间:0.39—-0.68)和denileukin diftitox 0.56(95%置信区间:0.35—-0.76)。完全缓解率(CRR)治疗后的任何时候和basiliximab daclizumab为0.55(95%置信区间CI: 0.42 - -0.68)和0.42(95%置信区间:0.29—-0.56),分别是优于inolimomab 0.30(95%置信区间:0.16—-0.51)和denileukin diftitox 0.37(95%置信区间:0.24—-0.52)。 The ORR and CRR were better after 1-month treatment with basiliximab and daclizumab than after treatment with inolimomab and denileukin diftitox. The incidence of the infection was higher after inolimomab treatment than after treatment with the other IL-2RAs. In conclusion, the efficacy and safety of different IL-2RAs varied. The response rate of basiliximab was the highest, followed by that of daclizumab. Prospective, randomized controlled trials are needed to compare the efficacy and safety of different IL-2RAs.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Inolimomab